Jitesh Chauhan
YOU?
Author Swipe
View article: Supplementary Figure 2 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Supplementary Figure 2 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Open
Supplementary Figure 2: Schema of antibody PIPE cloning and production of antibody variants.
View article: Figure 7 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Figure 7 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Open
Macrophage activation by FcγRIIIa-enhanced antibodies. A, Fluorometric analysis of ADCC/ADCP in 3.5-hour cocultures of macrophages and target cells (3:1) in the presence or absence of antibodies (0.1 μg/mL). Target cells were labele…
View article: Supplementary Figure 7 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Supplementary Figure 7 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Open
Supplementary Figure 7: ADCC measured by flow cytometric analysis using Zombie Green Fixable Viability dye in a 4-hour co-culture of target cells and purified NK cells (1:3 ratio) in the presence of engineered antibodies (0.1 ng/mL). Bars …
View article: Figure 8 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Figure 8 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Open
In vivo effects of Fc-enhanced IgG1 antibodies. A, HCC1954 growth curves in mice injected with 107 PBMCs and treated weekly with 2 mg/kg antibody or PBS. B, Mouse weight measurement. C, Kaplan–Meier p…
View article: Supplementary Figure 5 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Supplementary Figure 5 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Open
Supplementary Figure 5: SPR analysis curves of antibody variants to each FcγR. His-tagged FcγR were captured by immobilized His tag antibodies on the surface of the SPR chip, and antibody variants were flowed over the FcγR-bound surface ov…
View article: Figure 2 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Figure 2 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Open
Transcriptomic analysis of FCGR and immune cell expression in patients before and after chemotherapy and immunotherapy treatment. A, Uniform Manifold Approximation and Projection (UMAP) visualization of tumor-infiltrating lym…
View article: Figure 4 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Figure 4 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Open
Cell binding and Fab-mediated functionality of FcγRIIIa-enhanced antibodies. A, Binding of anti-HER2 and anti-FRα IgG variants (0.03–10 µg/mL) to NK cells evaluated by flow cytometry (n = 4). B and C, Binding of…
View article: Data from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Data from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Open
Fc engineering to enhance antibody effector functions harbors the potential to improve therapeutic effects. Understanding FcγR expression and distribution in the tumor microenvironment prior to and following treatment may help guide immune…
View article: Supplementary Figure 8 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Supplementary Figure 8 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Open
Supplementary Figure 8: Effects of antibodies in tumor bearing mice engrafted with human CD34+ cells. (Left) Kaplan-Meier plot of probability of survival of mice (death occurring when tumor reached 15 × 15mm). Statistical significance was …
View article: Figure 1 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Figure 1 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Open
Transcriptomic analysis of FcγR and immune cell expression. A and B, Uniform Manifold Approximation and Projection (UMAP) visualization of tumor-infiltrating lymphocytes from pretreatment samples, HER2+ (A) and TNBC (G…
View article: Figure 5 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Figure 5 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Open
FcγRIIIa-enhanced antibodies engender NK cell activation above IgG1-WT. A, CD69 and CD107a expression on NK cells measured by flow cytometry following cross-linking of FcγRIIIa by engineered antibodies (20 μg/mL) and anti-F(ab′)
View article: Supplementary Table 3 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Supplementary Table 3 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Open
Supplementary Table 3: Antibody variant production yield from transient transfection of 30mL Expi293F cells.
View article: An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Open
Fc engineering to enhance antibody effector functions harbors the potential to improve therapeutic effects. Understanding FcγR expression and distribution in the tumor microenvironment prior to and following treatment may help guide immune…
View article: Molecular Signatures and Functional Pathways of Human Monocytes and Macrophages in Allergy: An <scp>EAACI AllergoOncology</scp> Scoping Review
Molecular Signatures and Functional Pathways of Human Monocytes and Macrophages in Allergy: An <span>EAACI AllergoOncology</span> Scoping Review Open
AllergoOncology explores the intersection of allergic diseases and cancer, focusing on shared immune mechanisms. While monocytes and macrophages are extensively studied in cancer, their roles in allergic diseases remain underexplored. To a…
View article: AllergoOncology: Non-Allergic Urticarial Skin Reactions Associated with MOv18 IgE, a First-in-Class IgE Antibody Recognising FRα
AllergoOncology: Non-Allergic Urticarial Skin Reactions Associated with MOv18 IgE, a First-in-Class IgE Antibody Recognising FRα Open
View article: Tuning antibody stability and function by rational designs of framework mutations
Tuning antibody stability and function by rational designs of framework mutations Open
Artificial intelligence and machine learning models have been developed to engineer antibodies for specific recognition of antigens. These approaches, however, often focus on the antibody complementarity-determining region (CDR) whilst ign…
View article: Basophil Activation Test: Bridging Allergy and Oncology for Diagnostic, Therapeutic and Prognostic Applications in <scp>AllergoOncology</scp>: An <scp>EAACI</scp> Position Paper
Basophil Activation Test: Bridging Allergy and Oncology for Diagnostic, Therapeutic and Prognostic Applications in <span>AllergoOncology</span>: An <span>EAACI</span> Position Paper Open
The basophil activation test (BAT) is gaining increasing relevance as an ex vivo functional assay in allergy to evaluate IgE‐mediated hypersensitivity reactions to food allergens, venoms, and drugs and to monitor tolerance induction. Estab…
View article: Assessment of biophysical properties of the first-in-class anti-cancer IgE antibody drug MOv18 IgE demonstrates monomeric purity and stability
Assessment of biophysical properties of the first-in-class anti-cancer IgE antibody drug MOv18 IgE demonstrates monomeric purity and stability Open
Therapeutic monoclonal antibodies, which are almost exclusively IgG isotypes, show significant promise but are prone to poor solution stability, including aggregation and elevated solution viscosity at dose-relevant concentrations. Recombi…
View article: Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma
Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma Open
Background The majority of patients with melanoma develop immune-related adverse events (irAEs), and over half do not respond to anti-PD-1 (Programmed cell death protein 1) checkpoint inhibitor (CPI) immunotherapy. Accurate predictive biom…
View article: Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg cell interaction
Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg cell interaction Open
Ovarian cancer is the most lethal gynaecological cancer and treatment options remain limited. In a recent first-in-class Phase I trial, the monoclonal IgE antibody MOv18, specific for the tumour-associated antigen Folate Receptor-α, was we…
View article: Tuning antibody stability and function by rational designs of framework mutations
Tuning antibody stability and function by rational designs of framework mutations Open
Artificial intelligence and machine learning models have been developed to engineer antibodies for specific recognition of antigens, however these approaches often focus on the antibody complementarity determining region (CDR) whilst ignor…
View article: Non‐Allergic Urticarial Skin Reactions Associated With <scp>MOv18 IgE</scp>, a First‐In‐Class <scp>IgE</scp> Antibody Recognising Folate Receptor Alpha
Non‐Allergic Urticarial Skin Reactions Associated With <span>MOv18 IgE</span>, a First‐In‐Class <span>IgE</span> Antibody Recognising Folate Receptor Alpha Open
Background IgE antibodies directed against cancer antigens have demonstrated potent anti‐tumour effects in pre‐clinical studies. MOv18 IgE, the first‐in‐class IgE recognising the cancer antigen folate receptor alpha (FRα), showed prelimina…
View article: Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors
Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors Open
Background Anti-human epidermal growth factor receptor 2 (HER2) IgG1-based antibody therapies significantly improve cancer prognosis, yet intrinsic or acquired resistance to fragment antigen-binding (Fab)-mediated direct effects commonly o…
View article: An IgE antibody targeting HER2 identified by clonal selection restricts breast cancer growth via immune-stimulating activities
An IgE antibody targeting HER2 identified by clonal selection restricts breast cancer growth via immune-stimulating activities Open
View article: Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production
Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production Open
Antibodies used for cancer therapy are monoclonal IgGs, but tumor-targeting IgE antibodies have shown enhanced effector cell potency against cancer in preclinical models. Research-grade recombinant IgE antibodies have been generated and st…
View article: Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma
Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma Open
Immunotherapies, including checkpoint inhibitor antibodies, have precipitated significant improvements in clinical outcomes for melanoma. However, approximately half of patients do not benefit from approved treatments. Additionally, apart …
View article: Granulocytes and mast cells in AllergoOncology—Bridging allergy to cancer: An <scp>EAACI</scp> position paper
Granulocytes and mast cells in AllergoOncology—Bridging allergy to cancer: An <span>EAACI</span> position paper Open
Derived from the myeloid lineage, granulocytes, including basophils, eosinophils, and neutrophils, along with mast cells, play important, often disparate, roles across the allergic disease spectrum. While these cells and their mediators ar…
View article: Protective effects of allergic diseases in <scp>COVID</scp>‐19 outcomes: A retrospective cohort study in <scp>UK</scp> Biobank in the general population and in patients with cancer
Protective effects of allergic diseases in <span>COVID</span>‐19 outcomes: A retrospective cohort study in <span>UK</span> Biobank in the general population and in patients with cancer Open
To the Editor, SARS-CoV-2 (COVID-19) infection can lead to acute respiratory distress syndrome (ARDS) in severe cases. Preliminary evidence during the COVID-19 pandemic suggested that respiratory diseases could be associated with poorer ou…
View article: Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial Open
View article: B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma
B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma Open
B cells are known to contribute to the anti-tumor immune response, especially in immunogenic tumors such as melanoma, yet humoral immunity has not been characterized in these cancers to detail. Here we show comprehensive phenotyping in sam…